The Zhitong Finance App learned that on August 19, Hong Kong stock innovative pharmaceutical company Genting Xinyao (01952.HK) disclosed its 2026 interim results. During the reporting period, the company achieved total revenue of RMB 1,148 billion, up 157% year on year; after excluding non-cash items, gross margin reached 73.7%, realized net profit of RMB 97.23 million under international financial reporting standards, net loss narrowed 98% year on year under international financial standards, and operating expenses as a share of revenue fell 64.0 percentage points year on year, reflecting the continuous improvement of the company's operating efficiency and execution efficiency.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.